Latest Conference Coverage


Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD

Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD

July 30th 2024

The co-founder and chief science officer at Longeveron provided commentary on the therapeutic potential of Lomecel-B, a living cell product in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]


Y-Secretase Modulator RG6289 Produces Dose-Dependent Shift of Amyloid-ß Monomers in Phase 1 Study

Y-Secretase Modulator RG6289 Produces Dose-Dependent Shift of Amyloid-ß Monomers in Phase 1 Study

July 30th 2024

A small clinical trial showed RG6289 dose-dependently altered amyloid-ß monomers in CSF, supporting its development for Alzheimer's disease.


 Paul Edison, MD, PhD

Potential Cognitive Benefits of Using GLP-1 Analogs for Alzheimer Disease Treatment: Paul Edison, MD, PhD

July 30th 2024

The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]


Education and Number of Household Members Negatively Impacts Cognitive Outcomes in Latino Individuals

Education and Number of Household Members Negatively Impacts Cognitive Outcomes in Latino Individuals

July 30th 2024

In Latino individuals, larger household size negatively affects MoCA scores, while higher education positively impacts cognitive outcomes, per SERVE OC trial data.


Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN

Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN

July 29th 2024

The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]


Innovative Phase 2 Proof-of-Concept Trial to Test Effects of Benfotiamine as Alzheimer Treatment

Innovative Phase 2 Proof-of-Concept Trial to Test Effects of Benfotiamine as Alzheimer Treatment

July 29th 2024

The trial will use phase 2a to determine the optimal dosage while phase 2b will assess efficacy and long-term safety of the optimized dose against a placebo arm.


Alzheimer Agent T3D-959 Demonstrates Disease-Modifying Effects in Phase 2 PIONEER Trial

Alzheimer Agent T3D-959 Demonstrates Disease-Modifying Effects in Phase 2 PIONEER Trial

July 29th 2024

The drug showed a strong safety profile and met primary endpoints, showing efficacy in slowing clinical and biological decline and supporting further investigation in a phase 2/3 trial.


Joan A. Casey, PhD

Exploring Wildfire Smoke Exposure and Risk of Dementia in an Older Patient Population: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPH

July 29th 2024

A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]


Alzheimer Vaccine ALZ-101 Shows Safety, Oligomer-Specific Humoral Immune Response in Early-Stage Trial

Alzheimer Vaccine ALZ-101 Shows Safety, Oligomer-Specific Humoral Immune Response in Early-Stage Trial

July 28th 2024

The vaccine induced a specific humoral immune response, positively affecting several AD-related biomarkers, and showed potential as a treatment for AD, with further trials planned.


Soeren Mattke, MD, DSc

Improving Alzheimer Disease Diagnosis Through Efficient Referrals of Blood Tests: Soeren Mattke, MD, DSc

July 28th 2024

The director of the Brain Health Observatory at the University of Southern California talked about integrating blood tests into primary care to better triage patients with Alzheimer disease, reduce unnecessary referrals, and shorten appointment wait times. [WATCH TIME: 7 minutes]


Michael Soileau, MD, FAAN  (Credit: LinkedIn)

Transforming the Landscape of Parkinson Disease Care Through Patient-Centric Focus

July 26th 2024

Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.


Episode 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

Episode 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

July 26th 2024

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Douglas Wajda, PhD. [LISTEN TIME: 13 minutes]


Anvi Gadani, MD  (Credit: Medstar Health)

Advances in Therapeutic Management for Parkinson Disease and Essential Tremor

July 25th 2024

Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.


NeuroVoices: David Shprecher, DO, MSci, FAAN, on Current and Future Directions in Biomarker Testing for Atypical Parkinsonism

NeuroVoices: David Shprecher, DO, MSci, FAAN, on Current and Future Directions in Biomarker Testing for Atypical Parkinsonism

Published: July 24th 2024 | Updated: July 30th 2024

The director of movement disorders at the Banner Sun Health Research Institute talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain.


Patricia K. Coyle, MD

Potential of BTK Inhibitors for Primary Progressive Multiple Sclerosis: Patricia K. Coyle, MD

Published: July 23rd 2024 | Updated: June 11th 2024

The professor of neurology at Stony Brook Medicine talked about the promising potential in ongoing studies assessing BTK inhibitors as treatment for primary progressive multiple sclerosis. [WATCH TIME: 3 minutes]


Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

Optimizing Localization in Multiple Sclerosis Diagnosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

July 23rd 2024

The assistant professor at Hunter College talked about the approach of localization to prevent misdiagnoses of multiple sclerosis and ensure patients receive appropriate treatment. [WATCH TIME: 3 minutes]


A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease

A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease

Published: July 22nd 2024 | Updated: July 24th 2024

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.


Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

Streamlining MS Diagnosis and Treatment Through Effective Localization: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

July 16th 2024

The assistant professor at Hunter College talked about how to effectively diagnose and treat multiple sclerosis through localization and active listening of the patient's history and symptoms. [WATCH TIME: 7 minutes]


Kathy Zackowski, PhD, OTR

Promoting Early Rehabilitation and Wellness for Patients With Multiple Sclerosis: Kathy Zackowski, PhD, OTR

Published: July 15th 2024 | Updated: July 16th 2024

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]


Overviewing the XYLO Study and Low-Sodium Oxybate’s Impact on Blood Pressure: Phil Jochelson, MD

Overviewing the XYLO Study and Low-Sodium Oxybate’s Impact on Blood Pressure: Phil Jochelson, MD

July 12th 2024

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]


Charbel Moussa, MBBS, PhD

Advances in Multifaceted Drug Approaches for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

July 10th 2024

The associate professor of neurology at Georgetown University Medical Center talked about innovative treatments for dementia in movement disorders that target multiple mechanisms to effectively modify the disease. [WATCH TIME: 7 minutes]


NeuroVoices: Kelly Papesh, DNP, APRN, FNP-BC, on Understanding Patient Silence for Movement Disorder Concerns in the Clinical Setting

NeuroVoices: Kelly Papesh, DNP, APRN, FNP-BC, on Understanding Patient Silence for Movement Disorder Concerns in the Clinical Setting

Published: July 10th 2024 | Updated: July 10th 2024

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.


Charbel Moussa, MBBS, PhD

Emerging Promise of Tyrosine Kinase Inhibitors in Neurological Disease Treatment: Charbel Moussa, MBBS, PhD

July 8th 2024

The associate professor of neurology at Georgetown University Medical Center talked about the potential of tyrosine kinase inhibitors in treating neurodegenerative diseases. [WATCH TIME: 7 minutes]


Kelly Papesh, DNP, APRN, FNP-BC

The Importance of Open Communication in Patient Care: Kelly Papesh, DNP, APRN, FNP-BC

July 7th 2024

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]


Patricia Clark, CNP

Improving Medication Management and Education of Parkinson Disease in Hospital Settings: Patricia Clark, CNP

July 7th 2024

The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]


Michael Soileau, MD, FAAN

The Challenges and Innovations in Parkinson Treatment: Michael Soileau, MD, FAAN

July 6th 2024

The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]


Anvi Gadani, MD

Importance of Informed Patient Conversations Regarding Subcutaneous Infusion Pumps for PD: Anvi Gadani, MD

July 5th 2024

The assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]

© 2024 MJH Life Sciences

All rights reserved.